Key Documents
OP68
Anti-p21WAF1 (Ab-3) Mouse mAb (DF10)
liquid, clone DF10, Calbiochem®
Synonym(s):
Anti-CIP1, Anti-SD11, Anti-p21, Anti-WAF
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
biological source
mouse
Quality Level
antibody product type
primary antibodies
clone
DF10, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
should not react with
mouse, rat
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
General description
Purified mouse monoclonal antibody generated by immunizing F1 mice with the specified immunogen and fusing splenocytes with SP2/0 cells. Recognizes the ~21 kDa p21WAF1 protein.
Recognizes the ~21 kDa p21WAF1 protein in skin or colon tissue and in cells expressing wild-type p53 (e.g. Hs27 or U205 cells treated with DNA damaging agents).
Immunogen
full-length, recombinant human p21WAF1
Application
Immunoblotting (1 µg/ml)
Immunoprecipitation (2 µg/sample)
Immunoprecipitation (2 µg/sample)
Packaging
Please refer to vial label for lot-specific concentration.
Analysis Note
Positive Control
Any cell line expressing wild-type p53 (e.g. Hs27 or U2Os cells treated with DNA-damaging agents)
Any cell line expressing wild-type p53 (e.g. Hs27 or U2Os cells treated with DNA-damaging agents)
Other Notes
Agarwal, M.L., et al. 1995 Proc. Natl. Acad. Sci. USA92, 8493.
Chen, Y.Q., et al. 1995. Int. J. Oncology7, 889.
Deng, C., et al. 1995 Cell82, 675.
El-Deiry, W.S., et al. 1995 Cancer Res.55, 2910.
Waldman, T., et al. 1995 Cancer Res.55, 5187.
El-Deiry, W.S., et al. 1994 Cancer Res.54, 1169.
Elbendary, A., et al. 1994 Cell Growth Diff.5, 1301.
Li, R., et al. 1994 Nature371, 534.
Michieli, P., et al. 1994 Cancer Res. 54, 3391.
Noda, A., et al.1994. Exp. Cell Res.211, 90.
El-Deiry, W.S., et al. 1993. Cell75 817.
Gu, Y., et al. 1993. Nature366, 707.
Harper, J.W., et al. 1993 Cell75, 805.
Xiong, Y., et al. 1993. Genes Devel.7, 1572.
Xiong, Y., et al. 1993. Nature366, 701.
Xiong, Y., et al. 1992. Cell71, 505.
Chen, Y.Q., et al. 1995. Int. J. Oncology7, 889.
Deng, C., et al. 1995 Cell82, 675.
El-Deiry, W.S., et al. 1995 Cancer Res.55, 2910.
Waldman, T., et al. 1995 Cancer Res.55, 5187.
El-Deiry, W.S., et al. 1994 Cancer Res.54, 1169.
Elbendary, A., et al. 1994 Cell Growth Diff.5, 1301.
Li, R., et al. 1994 Nature371, 534.
Michieli, P., et al. 1994 Cancer Res. 54, 3391.
Noda, A., et al.1994. Exp. Cell Res.211, 90.
El-Deiry, W.S., et al. 1993. Cell75 817.
Gu, Y., et al. 1993. Nature366, 707.
Harper, J.W., et al. 1993 Cell75, 805.
Xiong, Y., et al. 1993. Genes Devel.7, 1572.
Xiong, Y., et al. 1993. Nature366, 701.
Xiong, Y., et al. 1992. Cell71, 505.
May also detect unidentified higher molecular weight proteins by immunoblotting. Maximal p21WAF1 expression requires wild type p53 activity. Treatment of U2OS cells with DNA damaging agents induces wild type p53 expression which in turn activates WAF1 expression. Serum stimulation of quiescent cells will give low level WAF1 expression independent of p53 expression. This antibody can also immunoprecipitate proteins associated with p21WAF1. For immunoblotting applications, antigen/antibody complexes are best visualized using chemiluminescence. Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Not finding the right product?
Try our Product Selector Tool.
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J W Harper et al.
Cell, 75(4), 805-816 (1993-11-19)
The cyclin-dependent kinase Cdk2 associates with cyclins A, D, and E and has been implicated in the control of the G1 to S phase transition in mammals. To identify potential Cdk2 regulators, we have employed an improved two-hybrid system to
A Elbendary et al.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 5(12), 1301-1307 (1994-12-01)
Transforming growth factor beta (TGF beta) is an important regulator of cellular proliferation. In normal ovarian epithelial cells, TGF beta acts to inhibit growth. However, in ovarian cancer cell lines, this effect is usually lost. Although the regulatory pathway of
Y Xiong et al.
Nature, 366(6456), 701-704 (1993-12-16)
Deregulation of cell proliferation is a hallmark of neoplastic transformation. Alteration in growth control pathways must translate into changes in the cell-cycle regulatory machinery, but the mechanism by which this occurs is largely unknown. Compared with normal human fibroblasts, cells
W S el-Deiry et al.
Cancer research, 55(13), 2910-2919 (1995-07-01)
The p53-regulated gene product p21WAF1/CIP1 is the prototype of a family of small proteins that negatively regulate the cell cycle. To learn more about p21WAF1/CIP1 regulation in vivo, monoclonal antibodies were developed for immunohistochemistry. These revealed that p21WAF1/CIP1 expression followed
C Deng et al.
Cell, 82(4), 675-684 (1995-08-25)
p21CIP1/WAF1 is a CDK inhibitor regulated by the tumor suppressor p53 and is hypothesized to mediate G1 arrest. p53 has been suggested to derive anti-oncogenic properties from this relationship. To test these notions, we created mice lacking p21CIP1/WAF1. They develop
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service